Function of ERbB2 in Cancer and the development of tailored treatment for Gastric Cancer: Signaling routes to treatment approaches

Introduction: Molecularly targeted therapies, such as those targeting erb-b2 receptor tyrosine kinase 2 (ERbB2) also known as human epidermal growth factor receptor 2 (HER2), are anticipated to improve the current status of systemic treatment beyond conventional cytotoxic therapy. Recent developments in molecular targeted treatments, particularly those that focus on human epidermal growth factor receptor 2, have significantly improved therapeutic potential for patients with gastric cancer. Human epidermal growth factor receptor receptors are the crucial factor in the development and progression of gastric cancer. A portion of gastric cancers exhibit rising levels or amplification of ERbB2 gene, which can stimulate tumor growth and the spread of cancer. The status of ERbB2 is also critical for managing treatment approaches, especially in recognizing patients who might be benefited from targeted therapies. Methodology: PubMed, NIH, Scopus, Web of Science, and Google Scholar databases were used to do the literature search. Important information for this review was gathered through the analysis of case reports, retrospective research, clinical trials, clinical recommendations, narrative reviews, and online resources.Topic: This article will discuss the complex molecular processes through which ERbB2 plays a role in cancer development, highlighting its impact on signaling pathways that promote gastric cancer and research progress within the realm of clinical trials. This review will also analyze the progress in ERbB2 targeted therapy and significance of ERbB2 as a target for advanced therapy.Conclusion: Research is being conducted on targeted therapeutics for gastric cancer (GC). A considerable number of clinical investigations indicate that ERbB2 (HER2) may function as a great therapeutic target and biomarker in GC. Although GC treatment has advanced significantly, there are still numerous challenges to be solved.